Literature DB >> 25040887

Molecular mechanism of allosteric modulation at GPCRs: insight from a binding kinetics study at the human A1 adenosine receptor.

Dong Guo1, Suzanne N Venhorst, Arnault Massink, Jacobus P D van Veldhoven, Georges Vauquelin, Adriaan P IJzerman, Laura H Heitman.   

Abstract

BACKGROUND AND
PURPOSE: Many GPCRs can be allosterically modulated by small-molecule ligands. This modulation is best understood in terms of the kinetics of the ligand-receptor interaction. However, many current kinetic assays require at least the (radio)labelling of the orthosteric ligand, which is impractical for studying a range of ligands. Here, we describe the application of a so-called competition association assay at the adenosine A1 receptor for this purpose. EXPERIMENTAL APPROACH: We used a competition association assay to examine the binding kinetics of several unlabelled orthosteric agonists of the A1 receptor in the absence or presence of two allosteric modulators. We also tested three bitopic ligands, in which an orthosteric and an allosteric pharmacophore were covalently linked with different spacer lengths. The relevance of the competition association assay for the binding kinetics of the bitopic ligands was also explored by analysing simulated data. KEY
RESULTS: The binding kinetics of an unlabelled orthosteric ligand were affected by the addition of an allosteric modulator and such effects were probe- and concentration-dependent. Covalently linking the orthosteric and allosteric pharmacophores into one bitopic molecule had a substantial effect on the overall on- or off-rate. CONCLUSION AND IMPLICATIONS: The competition association assay is a useful tool for exploring the allosteric modulation of the human adenosine A1 receptor. This assay may have general applicability to study allosteric modulation at other GPCRs as well.
© 2014 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25040887      PMCID: PMC4294041          DOI: 10.1111/bph.12836

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  40 in total

Review 1.  Drug-target residence time--a case for G protein-coupled receptors.

Authors:  Dong Guo; Julia M Hillger; Adriaan P IJzerman; Laura H Heitman
Journal:  Med Res Rev       Date:  2014-02-18       Impact factor: 12.944

2.  Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time.

Authors:  Georges Vauquelin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-06-28       Impact factor: 3.000

Review 3.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

Review 4.  Emerging opportunities for allosteric modulation of G-protein coupled receptors.

Authors:  Ching-I Anderson Wang; Richard J Lewis
Journal:  Biochem Pharmacol       Date:  2012-09-11       Impact factor: 5.858

Review 5.  Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

Review 6.  Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.

Authors:  Briana J Davie; Arthur Christopoulos; Peter J Scammells
Journal:  ACS Chem Neurosci       Date:  2013-05-23       Impact factor: 4.418

7.  A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor.

Authors:  Tod Steinfeld; Mathai Mammen; Jacqueline A M Smith; Richard D Wilson; Jeffrey R Jasper
Journal:  Mol Pharmacol       Date:  2007-05-03       Impact factor: 4.436

8.  2-Chloro-N6-cyclopentyladenosine: a highly selective agonist at A1 adenosine receptors.

Authors:  M J Lohse; K N Klotz; U Schwabe; G Cristalli; S Vittori; M Grifantini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-06       Impact factor: 3.000

Review 9.  Allosteric modulation of the adenosine family of receptors.

Authors:  Zhan-Guo Gao; Soo-Kyung Kim; Adriaan P Ijzerman; Kenneth A Jacobson
Journal:  Mini Rev Med Chem       Date:  2005-06       Impact factor: 3.862

10.  The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands.

Authors:  Adam J Pawson; Joanna L Sharman; Helen E Benson; Elena Faccenda; Stephen P H Alexander; O Peter Buneman; Anthony P Davenport; John C McGrath; John A Peters; Christopher Southan; Michael Spedding; Wenyuan Yu; Anthony J Harmar
Journal:  Nucleic Acids Res       Date:  2013-11-14       Impact factor: 16.971

View more
  7 in total

Review 1.  Perspective: Implications of Ligand-Receptor Binding Kinetics for Therapeutic Targeting of G Protein-Coupled Receptors.

Authors:  Wijnand J C van der Velden; Laura H Heitman; Mette M Rosenkilde
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-18

2.  Mass spectrometry-based ligand binding assays on adenosine A1 and A2A receptors.

Authors:  A Massink; M Holzheimer; A Hölscher; J Louvel; D Guo; G Spijksma; T Hankemeier; A P IJzerman
Journal:  Purinergic Signal       Date:  2015-10-19       Impact factor: 3.765

Review 3.  Binding kinetics of ligands acting at GPCRs.

Authors:  David A Sykes; Leigh A Stoddart; Laura E Kilpatrick; Stephen J Hill
Journal:  Mol Cell Endocrinol       Date:  2019-02-08       Impact factor: 4.102

4.  Analysis of equilibrium binding of an orthosteric tracer and two allosteric modulators.

Authors:  Jan Jakubík; Alena Randáková; Esam E El-Fakahany; Vladimír Doležal
Journal:  PLoS One       Date:  2019-03-27       Impact factor: 3.240

Review 5.  International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.

Authors:  Adriaan P IJzerman; Kenneth A Jacobson; Christa E Müller; Bruce N Cronstein; Rodrigo A Cunha
Journal:  Pharmacol Rev       Date:  2022-04       Impact factor: 25.468

Review 6.  Gaussian accelerated molecular dynamics for elucidation of drug pathways.

Authors:  Apurba Bhattarai; Yinglong Miao
Journal:  Expert Opin Drug Discov       Date:  2018-10-29       Impact factor: 6.098

7.  Hit-to-lead and lead optimization binding free energy calculations for G protein-coupled receptors.

Authors:  Shunzhou Wan; Andrew Potterton; Fouad S Husseini; David W Wright; Alexander Heifetz; Maciej Malawski; Andrea Townsend-Nicholson; Peter V Coveney
Journal:  Interface Focus       Date:  2020-10-16       Impact factor: 3.906

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.